1 | INTRODUCTION

Type 2 diabetes (T2D) is associated with increased risks of morbidity and mortality, and the prevalence of T2D is increasing with a westernized lifestyle and aging. The prevalence of diabetes is increasing globally, particularly in Asia. Japan has the 10th highest rate in the world (China, India, USA, Brazil, Indonesia, Mexico, Egypt, Germany, Turkey, and Japan). The Diabetes Atlas of the International Diabetes Federation shows that approximately 4.5 million deaths in 2011 could have been attributed to diabetes, representing more than 8% of all-cause mortality. Also, T2D is associated with increased medical costs. Table 1 shows diabetes trends in Japan according to the time axis. Therefore, overcoming T2D is an urgent issue in Japan.

Japan has adopted the universal medical care insurance system, where all people are insured by one of the public medical insurance systems. In 2003, the Health Promotion Law was enforced, aiming to prevent lifestyle-related diseases including T2D. Now, it has become mandatory for all Japanese adults to undergo health checkups provided by public medical care insurance at least once a year. There are two main types of statutory health checkup programs: (i) workplace health checkup programs managed by employers (workplace setting), and (ii) community health checkup programs managed by municipalities (community setting) for self-employed, unemployed, and retired individuals. People are registered at healthcare divisions in their
This review will focus on the effectiveness of a diabetes prevention program (recruitment, target population, method of intervention, and evaluation) in the real world and insights from the JDPP and J-DOIT1. We will provide insights by answering a series of questions.

## 2 | QUESTION 1: HOW EFFECTIVE IS INTERVENTION TO PREVENT OR DELAY T2D IN HIGH-RISK SUBJECTS?

Goal-focused individualized intervention is the most effective to prevent or delay T2D in high-risk subjects with IGT and obesity. In the Finnish DPS study, 522 middle-aged (mean age: 55 years, mean BMI: 31 kg/m²) subjects with IGT and obesity were randomized to receive either brief diet and exercise counseling (control group) or intensive individualized instruction on weight reduction, food intake, and guidance on increasing physical activity (intervention group). The subjects in the intervention group were given detailed advice on how to achieve five goals (Table 2). The dietary advice was tailored to each subject on the basis of 3-day dietary records. Healthy food choices such as whole-grain products, vegetables, fruits, low-fat milk and meat products, soft margarines, and vegetable oils rich in monounsaturated fatty acids were recommended. Each subject in the intervention group underwent seven sessions with a nutritionist during the first year of the study and one session every 3 months thereafter. These subjects also received individual guidance on increasing their level of physical activity. Endurance exercise such as walking and swimming was recommended. Supervised, progressive, individually tailored, circuit-type resistance-training sessions were also provided. In the US DPP study, 3234 middle-aged (mean age: 51 years, mean BMI: 34 kg/m²) subjects with IGT and obesity were randomized to one of three intervention groups, which included structured intensive diet and exercise counseling (16 sessions) by lifestyle coaches. The two major goals of the DPP lifestyle intervention were a minimum of 7% weight loss and a minimum of 150 min/wk of physical activity. The DPP also included behavioral self-management strategies, supervised physical activity, and a “toolbox” of adherence strategies. The reduction in the risk of T2D was 58% over 3 years both in the Finnish DPS and US DPP. The main driving forces of diabetes programs seem to be weight loss and increased physical activity. Increased physical activity was important to help sustain such weight loss. The JDPP Research Group

| TARGET GOAL | FINNS DPP | US DPP | JDPP | J-DOIT1 |
|-------------|-----------|--------|------|---------|
| Weight reduction | >5% | >7% | >5% in overweight and obesity | >5% in obesity and >3% in overweight |
| Exercise | >4 h/wk | >150 min/wk | >700 kcal/wk | ≥10 000 steps/d |
| Fat intake | <30% of energy intake | <25% of energy intake | - | - |
| Saturated fat intake | <10% of energy intake | - | - | - |
| Fiber intake | ≥15 g/1000 kcal | - | - | ≥350 g of vegetables/d |
| Restriction on alcohol | - | - | - | ≥23 g of ethanol |

DPP, Diabetes Prevention Program; DPS, Diabetes Prevention Study; J-DOIT1, Japan Diabetes Outcome Trial 1; JDPP, Japan Diabetes Prevention Program.
adopted weight and exercise goals: 1) to reduce the initial body weight by 5% in overweight and obese subjects, and 2) to increase energy expenditure due to leisure time physical activity (LTPA) by 700 kcal/wk. Moderate alcohol consumption was associated with a decreased risk of T2D, but heavy alcohol consumption was associated with an increased risk of T2D among lean men. Binge drinking (≥3 drinks per occasion) significantly increased the risk of future diabetes regardless of the frequency compared with <1 drink per occasion. Therefore, the J-DOIT1 Research group adopted the target goal of fiber intake and alcohol restriction in addition to the weight and exercise goals. The intervention arm received a 1-year telephone-delivered intervention provided by three private lifestyle support centers (at different frequencies: low-frequency (3 times), middle-frequency (6 times), and high-frequency (10 times) support calls). The intervention and control arms both received self-help devices such as a weight scale and pedometer. In the J-DOIT1, T2D developed in 115 participants in the intervention arm and 132 participants in the control arm (9.3%) during a median follow-up period of 4.2 years. Overall, the hazard ratio (HR) for the development of T2D in the intervention arm during 5.5 years was 1.00. In the subanalysis of the three lifestyle support centers, the HR was significantly reduced to 0.59 (95% CI 0.42 to 0.83; P=.02) for center C, which provided 10 telephone calls, while no beneficial effects on the incidence were found for centers A and B, which made telephone calls less frequently. 

3 | QUESTION 2: HOW DOES A DIABETES PREVENTION PROGRAM EFFECTIVELY TRANSLATE INTO THE REAL WORLD?

Figure 1 shows diabetes prevention studies in the world. Translational research can be varied for numerous settings. It is feasible, but almost all outcomes involve weight change. It is less effective, and there have been no long-term follow-ups. Structured diabetes programs were translated into the real world (Table 3). DPP-based studies were conducted in various settings. Participants included minority and low-income members of society. The Finnish DPS study was translated in other areas. Translational studies are in other areas of North-America, the EU, China, India, and Australia. Settings of the translational research varied: hospital outpatients, hospital inpatients, primary care, the community, workplace, and church. In the DPP-based translational research, sample sizes in the studies ranged from 8 to 1003 participants (Table 4). Participants were predominantly female, and in studies that evaluated depressive symptoms, the psychosocial comorbidity rate was much higher than in the DPP. The main outcome of the translational research is almost always weight change and less effective compared with DPP and the Finnish DPS. Effectiveness in translational research can be improved by maximizing guideline adherence.
QUESTION 3: WHO IS THE TARGET POPULATION FOR PREVENTING DIABETES?

The Finnish DPS and US DPP targeted IGT subjects with obesity. IGT subjects with high HbA1c were a cost-effective target. Regarding impaired fasting glucose (IFG) subjects in the previous studies, IGT subjects with obesity are used as the target population for preventing T2D. The oral glucose tolerance test (OGTT) is useful for the detection of IGT, but it is troublesome for both patients and medical staff because of the requirement for frequent blood sampling, especially in a primary health care setting. IFG is also a risk factor for T2D. The J-DOIT1 adopted IFG subjects as the inclusion criteria. Glycated hemoglobin (HbA1c), a standard measure of chronic glycemia for managing diabetes, has been proposed to diagnose diabetes and identify people at risk. HbA1c levels predict incident diabetes, and lifestyle and metformin intervention reduced incident diabetes according to HbA1c defined in DPP. The subgroup analysis of the Zensharen study showed that the HR for developing diabetes reduced to 0.41 among IGT subjects, and to 0.24 among those with a higher baseline HbA1c. In the JDPP study, the mean follow-up was 2.3 years. The incidence of T2D was 2.7 and 5.1/100 person-years of follow-up in the intervention and control groups, respectively. For all participants, the intervention group tended to show a low cumulative incidence of T2D compared with the control group. There was no significant difference in HbA1c levels at the baseline between the groups. The cumulative incidence of T2D was significantly lower in the intervention group than control group among participants with baseline HbA1c levels ≥5.7%, while this was not found among participants with baseline HbA1c levels <5.7%. Lowering the HbA1c cutoff for prediabetes leads to less cost-effective preventive interventions. Assuming a conventional $50,000/QALY cost-effectiveness benchmark, HbA1c cutoffs of 5.7% or higher were found to be cost-effective. However, physicians and healthcare professionals in primary care are needed to attempt diabetes prevention for patients with or without a high risk for T2D.

**TABLE 5** Possible target population and target values for lifestyle intervention in the point of view of cost-effective approach

| Target variables | Target population and target value |
|------------------|-------------------------------------|
| Blood glucose    | High fasting plasma glucose (>100 mg/dL) |
|                  | High 2 h after OGTT                   |
|                  | IFG+IGT                              |
| BMI              | Overweight (BMI>23) and Obese         |
| HbA1c            | HbA1c>5.7%                            |
| Family history of T2D | Fist degree of diabetes              |
| Other situations | Elderly people (>65 y)                |
|                  | Metabolic Syndrome (Met5)             |
|                  | Nonalcoholic fatty liver disease (NAFLD) |

IFG, Impaired fasting glucose; IGT, Impaired glucose tolerance; OGTT, Oral glucose tolerance test; T2D, type 2 diabetes.
A cost-effective approach is needed to achieve T2D prevention in routine primary care and the general population. Family histories of T2D, metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD) are also associated with an increased risk of T2D. It is unclear whether MetS and NAFLD are associated with an increased risk of T2D. From the point of view of a cost-effective approach, possible target population and target values are summarized in Table 5.

IGT and IFG reveal not only prediabetes but also the risk of cardiovascular events in the future. Despite lifestyle interventions being mostly successful in preventing T2D, this intervention did not result in reductions in all-cause or cardiovascular mortality in real-world settings.

The method of lifestyle intervention varied. In a real-world setting, various behavioral strategies are used for lifestyle intervention. A cost-effective approach is needed. Group-based intervention and telephone-delivered lifestyle intervention are cost-effective. Furthermore, a fully automated lifestyle intervention facilitated by email, the Internet, and apps is required. A population approach is also cost-effective including healthy subjects. However, a population approach in Stockholm was not effective. Population approaches using self-care devices will be required in the future. Additional research including a more diverse population and a more realistic target population is needed.

**5 | QUESTION 4: WHAT ADDITIONAL RESEARCH IS NEEDED IN A REAL-WORLD SETTING?**

**TABLE 6** What additional research is needed in a real-world setting?

| Variables | Question |
|-----------|----------|
| Participants | More widely: Children, GDM, community-dwelling people, elderly Does diabetes prevention program reduce the incidence of T2D in elderly people with a high risk? |
| Outcome | Long-term outcome: Do diabetes prevention program reduce the incidence of major cardiovascular events and mortality? |
| Intervention | Development of high-quality cost-effective approach: Who conducts lifestyle intervention for preventing diabetes? (Primary care physician, health care provider, pharmacist, wellness supporter, peer supporter, etc.) How is lifestyle intervention delivered? (fully automated by email, internet, and app) |

GDM, Gestational diabetes mellitus; T2D, Type 2 diabetes.

**6 | CONCLUSION**

Evidence from translational studies for preventing T2D in the real world including JDPP and J-DOIT1 has been gradually accumulated. Additional research including a more diverse population and a more cost-effective approach is required in this field.

**ACKNOWLEDGEMENTS**

This work was partially supported by JSPS KAKENHI Grant Number JP 15K08580, and the Japanese Council for Science, Technology and Innovation, SIP (Project ID 14533567), “Technologies for creating next-generation agriculture, forestry and fisheries” (funding agency: Bio-oriented Technology Research Advancement Institution, NARO).

**CONFLICT OF INTEREST**

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

**REFERENCES**

1. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2:634–47.
2. Rhee EJ. Diabetes in Asians. Endocrinol Metab (Seoul). 2015;30:263–9.
3. IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. Diabetes Res Clin Pract. 2013;100(2):277–9.
4. Lkhagva D, Kuwabara K, Matsuda S, Gao Y, Babazono A. Assessing the impact of diabetes-related comorbidities and care on the hospitalization costs for patients with diabetes mellitus in Japan. J Diabetes Complications. 2012;26:129–36.
5. Implementation status of specific health checkups and specific health guidance. (2013) [cited 2016 Nov 14]. Available at: http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/dl/info03_h25_00.pdf
6. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.
7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
8. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35:723–30.
9. AI MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Aff (Millwood). 2012;31:67–75.
10. Sakane N, Sato J, Tuszita K, et al. Prevention of type 2 diabetes in a primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health. 2011;11:40.
11. Sakane N, Kotani K, Takahashi K, et al. Japan Diabetes Outcome Intervention Trial-1 (J-DOIT1), a nationwide cluster randomized trial
of type 2 diabetes prevention by telephone-delivered lifestyle support for high-risk subjects detected at health checkups: rationale, design, and recruitment. BMC Public Health. 2013;13:81.

12. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–2107.

13. Laaksonen DE, Lindström J, Lakka TA, et al. Finnish diabetes prevention study. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes. 2005;54:158–65.

14. Sato KK, Hayashi T, Harita N, et al. Relationship between drinking patterns and the risk of type 2 diabetes: the Kansai Healthcare Study. J Epidemiol Community Health. 2012;66:507–11.

15. Tsumura K, Hayashi T, Suematsu C, et al. Daily alcohol consumption and the risk of type 2 diabetes in Japanese men: the Osaka Health Survey. Diabetes Care. 1999;22:1432–7.

16. Heianza Y, Arase Y, Saito K, et al. Role of alcohol drinking pattern in type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 11 (TOPICS 11). Am J Clin Nutr. 2013;97:561–8.

17. Tabak RG, Sinclair KA, Baumann AA, et al. A review of diabetes prevention program translations: use of cultural adaptation and implementation research. Transl Behav Med. 2015;5:401–14.

18. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al. The European perspective of type 2 diabetes prevention: diabetes in Europe–prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes. 2008;116:167–72.

19. Ramachandran A, Snehaltha C, Mary S, et al. The Indian Diabetes Prevention Programme Shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDDP-1). Diabetologia. 2006;49:289–97.

20. Dunbar JA, Hernandez AL, Janus ED, et al. Challenges of diabetes prevention in the real world: results and lessons from the Melbourne Diabetes Prevention Study. BMJ Open Diabetes Res Care. 2015;3:e000131.

21. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152–62.

22. Kawahara T, Takahashi K, Inazu T, et al. Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2-day in-hospital diabetes educational program: the Joetsu Diabetes Prevention Trial. Diabetes Care. 2008;31:1949–54.

23. Hesselin AE, Rutten GE, Slootmaker SM, et al. Effects of a lifestyle program in subjects with Impaired Fasting Glucose, a pragmatic cluster-randomized controlled trial. BMC Farm Pract. 2015;16:183.

24. Ma J, King AC, Wilson SR, et al. Evaluation of lifestyle interventions to treat elevated cardiometabolic risk in primary care (E-LITE): a randomized controlled trial. BMC Farm Pract. 2009;10:71.

25. Ackermann RT, Finch EA, Brizendine E, et al. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med. 2008;35(4):357–63.

26. Finch EA, Kelly MS, Marrero DG, et al. Training YMCA wellness instructors to deliver an adapted version of the Diabetes Prevention Program lifestyle intervention. Diabetes Educ. 2009;35:224–8.

27. Wilson MG, DeJoy DM, Vandenberg R, et al. FUEL Your Life: a Translation of the Diabetes Prevention Program to Worksites. Am J Health Promot. 2016;30(3):188–97.

28. Whittimore R. A systematic review of the translational research on the Diabetes Prevention Program. Transl Behav Med. 2011;1:480–91.

29. Johnson M, Jones R, Freeman C, et al. Can diabetes prevention programmes be translated effectively into real-world settings and still deliver improved outcomes? A synthesis of evidence. Diabet Med. 2013;30:3–15.

30. Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. Implement Sci. 2015;10:172.

31. Dunkley AJ, Bodicoat DH, Greaves CJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care. 2014;37:922–33.

32. Sakamoto K, Kubo F, Yoshiuchi K, et al. Usefulness of a novel system for measuring glucose area under the curve while screening for glucose intolerance in outpatients. J Diabetes Investig. 2013;4:552–9.

33. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care. 2007;30:228–33.

34. Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care. 2015;38:51–8.

35. Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171:1352–60.

36. Sakane N, Sato J, Tsushita K, et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2014;2:e000003.

37. Zhuo X, Zhang P, Selvin E, et al. Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective. Am J Prev Med. 2012;42:374–81.

38. Miyakoshi T, Oka R, Nakasone Y, et al. Development of new diabetes risk scores on the basis of the current definition of diabetes in Japanese subjects. Endocr J. 2016;63(9):857–65.

39. Dunkley AJ, Charles K, Gray LJ, et al. Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis. Diabetes Obes Metab. 2012;14:616–25.

40. Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933–66.

41. Li G, Zhang P, Wang J, An Y, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–80.

42. Hopper I, Billah B, Skiba M, et al. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil. 2011;18:813–23.

43. Sherwin RS, Anderson RM, Buse JB, et al. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27(Suppl 1):S47–54.

44. Baker MK, Simpson K, Lloyd B, et al. Behavioral strategies in diabetes prevention programs: a systematic review of randomized controlled trials. Diabetes Res Clin Pract. 2011;91:1–12.

45. Block G, Azar KM, Romanelli RJ, et al. Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile phone: a randomized controlled trial among persons with pre-diabetes. J Med Internet Res. 2015;17:e240.

46. Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehneg C, Tillgren P. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care. 2009;25:350–8.